1 citations,
January 2022 in “Journal of The American Academy of Dermatology” Direct-to-consumer teledermatology platforms have financial conflicts of interest and lack proper patient care and follow-up.
June 2024 in “Military medicine” JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
April 2024 in “Pharmaceuticals” Bimatoprost helps with hair growth and eye conditions but can be costly and have side effects.
April 2024 in “International journal of impotence research” Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
February 2022 in “Cosmetic Dermatology” Platelet Rich Plasma (PRP) is increasingly used in cosmetic dermatology for hair loss, facial rejuvenation, and after cosmetic procedures, and can be stored for up to 90 days for daily home use.
August 2018 in “Journal of The American Academy of Dermatology” The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.
July 2024 in “European Journal of Medicinal Chemistry” New small molecule drugs could help treat hair loss.
November 2023 in “International journal of Ayurveda and pharma research” The herbal hair oil effectively promotes hair growth, nourishes the scalp, and prevents dandruff.
April 2023 in “Journal of Investigative Dermatology” Aminoacridine and Abemaciclib, especially combined with Minoxidil, show promise for treating hair loss.
September 2021 in “World journal of urology” The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
January 2020 in “Figshare” The study explored a possible link between finasteride use and suicide.
August 2018 in “Journal of The American Academy of Dermatology” Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.
August 2018 in “Journal of The American Academy of Dermatology” Finasteride use for hair loss is linked to an increased risk of suicidal thoughts and a higher risk of suicide.
Robotic-assisted hair transplant is effective and less painful, but needs more evaluation for long-term results.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
December 2010 in “Dermatologic Surgery” Finasteride's effectiveness on the frontal hair loss area is not well-studied or confirmed.
October 2021 in “International Journal of Andrology” Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.
September 2022 in “International Journal of Impotence Research” Public interest in finasteride's sexual side effects has significantly increased.
Microneedling may be an effective treatment for pattern hair loss.
July 2022 in “Journal of Investigative Dermatology” Dermatologists can use social media to better educate people about hair loss treatments.
Public awareness of finasteride's sexual side effects has increased, suggesting healthcare providers should discuss these risks more thoroughly with patients.
April 2015 in “Reactions Weekly” Finasteride toxicity information is limited, poor quality, and biased.
2 citations,
July 2022 in “Sexual Medicine” Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
September 2024 in “Journal of Cosmetic Dermatology” Low-dose oral minoxidil can cause serious side effects like heart issues, so use the lowest effective dose.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
January 2009 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Lasers and light treatments are now the most common ways to remove hair.
April 2023 in “European urology open science” Urologists should screen for mental health issues before and during finasteride treatment.
39 citations,
September 2015 in “Clinical Therapeutics” Teriflunomide was approved by the US FDA in 2012 for treating relapsing forms of multiple sclerosis (RMS) based on Phase II and III trials, including TEMSO, TOWER, and TOPIC. The 14 mg dose significantly reduced the annualized relapse rate and risk of disability progression, while the 7 mg dose also reduced relapse rates but not disability progression. MRI measures showed reduced lesion activity with both doses. Safety data indicated common adverse events like headache, alopecia, and nausea. Teriflunomide was considered an effective treatment option for RMS, with specific precautions for women of childbearing potential.